PHRI scientists stand out at conference

The European Society of Cardiology Congress in Munich, Germany next week will see a large delegation from the Population Health Research Institute (PHRI) of McMaster University and Hamilton Health Sciences take to the stage.

The presentations between Aug. 25 and 29 will include COMPASS trial results in context of other secondary prevention strategies, and PURE study findings that could influence global dietary guidelines.

There are several presentations on results from the COMPASS trial. John Eikelboom and Sonia Anand, both professors of medicine at McMaster, will talk on improved outcomes for patients with chronic coronary artery disease (CAD) and peripheral artery disease. Separately, Eikelboom will talk about reducing risk for these two diseases, and Anand will present on identifying patients at risk of CAD.

Andrew Mente, associate professor of McMaster’s Department of Health Research Methods, Evidence and Impact, will discuss the PURE study findings on nutrition, malnutrition and heart disease, particularly a discussion of global dietary patterns. Mahshid Dehghan, a nutritionist with PHRI, will speak at a session regarding debunking the myths about fats, carbs and alcohol.

Jessica Spence, who recently completed her residency in anesthesia at McMaster, will present on the VISION study, looking at the frequency, causes, and timing of 30-day mortality after non-cardiac surgery.

At an interactive session on pharmacology and pharmacotherapy, P.J. Devereaux, professor of medicine, will present new results from the MANAGE trial: Dabigatran versus placebo in patients with myocardial injury after non-cardiac surgery.

Harriette Van Spall, associate professor of medicine, will speak at two sessions on heart failure, and Salim Yusuf, PHRI director and professor of medicine, will moderate several sessions.

Learn more about PHRI at http://www.phri.ca/.

Eikelboom will also be discussing bleeding and cancer risk in patients with vascular disease treated with Rivaroxaban, from the COMPASS trial.